Abacavir

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Abacavir is an ofp drug in the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1998. Its mechanism of action is classified as Cytochrome P450 1A1 Inhibitors and Nucleoside Reverse Transcriptase Inhibitors. DrugCentral lists 3 molecular targets, including reverse transcriptas, pol and gag-pol. Recorded indications include Human immunodeficiency virus infection.

• Approval status: ofp (first approved 1998 by the FDA).
• Drug class: Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor.
• Mechanism of action: Cytochrome P450 1A1 Inhibitors; Nucleoside Reverse Transcriptase Inhibitors.
• Molecular targets: reverse transcriptas, pol and gag-pol (3 listed in DrugCentral).
• Indications: Human immunodeficiency virus infection.
• ATC code: J05AF06 (Nucleoside and nucleotide reverse transcriptase inhibitors).
• Molecular formula: C14H18N6O; molecular weight 286.34 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Human immunodeficiency virus infection

Contraindications (20)

• Acute pancreatitis
• Anemia
• Bone marrow depression
• Breastfeeding (mother)
• Chronic pancreatitis
• Disease of liver
• Disorder of muscle
• Drug Resistance to Anti-retroviral Therapy
• Hepatic failure
• HLA-B 5701 Positive Status
• Hypertriglyceridemia
• Kidney disease
• Lactic acidosis
• Large liver
• Myositis
• Neutropenic disorder
• Obesity
• Pancreatitis
• Steatosis of liver
• Toxic amblyopia

Mechanism & targets

• Mechanism of action (MoA): Cytochrome P450 1A1 Inhibitors; Nucleoside Reverse Transcriptase Inhibitors
• Established pharmacologic class: Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Molecular targets (3)

Target	Gene	Action	Activity
Reverse transcriptase	reverse transcriptas	unknown	IC50 6.89
Reverse transcriptase/RNaseH	pol	inhibitor	EC50 5.28
Gag-Pol polyprotein	gag-pol	unknown	EC50 5.28

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
1999-07-08	EMA	—	—
1998-12-17	FDA	—	VIIV HLTHCARE

ATC classification

ATC code	Therapeutic hierarchy
J05AF06	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Nucleoside and nucleotide reverse transcriptase inhibitors
J05AR02	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HIV infections, combinations
J05AR04	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HIV infections, combinations
J05AR13	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HIV infections, combinations

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: HLA-B · Testing Required
• FDA label: HLA-B · Testing Required
• HCSC label: HLA-B · Testing Required
• PMDA label: HLA-B · Informative PGx
• Swissmedic label: HLA-B · Testing Required

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Virologic failure	2034.2
Viral mutation identified	1572.3
Pathogen resistance	1171.5
Lipodystrophy acquired	971.3
Immune reconstitution inflammatory syndrome	801.2
Food allergy	724.4
Exposure during pregnancy	655.2
Foetal death	638.2
Immunodeficiency	627.6
Temperature regulation disorder	591.7
Drug resistance	569.6
Schizophrenia	538.9

Chemical structure

• Molecular formula: C₁₄H₁₈N₆O
• Molecular weight: 286.34 g/mol
• CAS number: 136470-78-5
• InChIKey: MCGSCOLBFJQGHM-SCZZXKLOSA-N
• PubChem CID: 441300

NC1=NC(NC2CC2)=C2N=CN([C@@H]3C[C@H](CO)C=C3)C2=N1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Abacavir used for?

DrugCentral lists the following indications for Abacavir: Human immunodeficiency virus infection.

How does Abacavir work?

Abacavir is classified as Cytochrome P450 1A1 Inhibitors and Nucleoside Reverse Transcriptase Inhibitors; its molecular targets in DrugCentral include reverse transcriptas, pol (inhibitor) and gag-pol.

When was Abacavir first approved?

Abacavir was first approved by the FDA in 1998.

What drug class does Abacavir belong to?

Abacavir is in the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor class.

What is the chemical formula of Abacavir?

Abacavir has the molecular formula C14H18N6O and a molecular weight of 286.34 g/mol.

Sources

• DrugCentral drug card 34 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1380 — compound record and bioactivity
• PubChem CID 441300 — chemical identifiers
• DrugBank DB01048 — drug record
• FDA UNII WR2TIP26VS — substance identity
• DailyMed: FDA labels for Abacavir — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.